Early trial tests custom vaccine to fight deadly brain cancer
NCT ID NCT05283109
Summary
This early-stage study is testing the safety of a personalized cancer vaccine for adults with a newly diagnosed, aggressive brain tumor called glioblastoma. The vaccine is designed to train the patient's immune system to attack the tumor. Researchers will give the vaccine to a small group of eligible patients and closely monitor for side effects and early signs of immune response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA, MALIGNANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Preston Robert Tisch Brain Tumor Center at Duke University
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.